Endo Health Solutions Inc: (NASD: ENDP)

$38.82

-0.48 (-1.22%)

Volume 1,090,225

Jun 18 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		38.61 - 39.47
	
		52wk Low - High
		25.01 - 39.82
	
		Previous Close
		39.30
	
		Avg. Volume
		1,820,788
	
		Industry
		MED-DRUGS
	
		Market Cap
		4.41 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.74
	
		P/E (F1)
		9.08
	
		Current Year Est.
		4.33
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		110 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            9.08
                        
                            PEG Ratio
                            1.30
                        
                            Current Year Est.
                            4.33
                        
                            Current Quarter Estimate
                            1.16
                        
                            Most Accurate Estimate
                            1.16
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            5.26
                        
                            Expected Earnings Growth
                            7.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Endo Pharmaceuticals Holdings Inc., through its wholly owned subsidiaries, Endo Pharmaceuticals Inc. and Endo Inc., is engaged in the research, development, sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain.   
Full ENDP Company Report

 Analyst Report on ENDP

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ENDP Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.16	1.10	4.33	3.81
Number of Estimates	13	12	13	14
Low Estimate	1.04	0.98	4.10	3.05
High Estimate	1.32	1.23	4.71	NA
Year Ago EPS	1.27	1.28	5.02	4.33
EPS Growth	-9.02%	-14.32%	-13.76%	-12.04%

More ENDP Estimates

Average Earnings Estimates for ENDP

EPS Growth for ENDP

Industry Analysis

Name	Symbol	Previous Close
ENDO PHARMACEUT	ENDP	39.30
JAZZ PHARMACEUT	JAZZ	69.50
SALIX PHARM-LTD	SLXP	66.21
SANTARUS INC	SNTS	21.52
USANA HLTH SCI	USNA	73.28
ARADIGM CORP	ARDM	0.18
CELL THERAPEUT	CTIC	1.25
DURECT CORP	DRRX	0.81
ELAN CP PLC ADR	ELN	13.49
FLAMEL TECH	FLML	6.21

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Endo to Trim Workforce

Jun 06, 2013

CRL for Endo Health's Aveed

Jun 03, 2013

Two Top Endo Executives Depart

May 30, 2013

Merck Enters into Strategic Deal

May 22, 2013

Setback for Endo Health on Opana ER

May 13, 2013

Earnings Beat at Endo Health, Sales Slip

May 08, 2013

Company News for May 8, 2013

May 08, 2013

Back to Neutral on Endo Health

Mar 06, 2013

More ENDP Zacks Commentary

Financials

EPS TTM	5.26
Sales	3,027
Net Income	-638
Price/Earnings	7.47
Price/Book	3.72
Price/Cash Flow	4.86
Price/Sales	1.45

More ENDP Financials

News

Endo Pharmaceuticals (ENDP) Showing Bullish Technicals With Resistance At $40.27 - Freshbrewedmedia

Jun 18, 2013

Shares of Endo Pharmaceuticals Under Pressure, Down 1.4% - Financial News Network Online - Market Movers

Jun 18, 2013

Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROA - Benzinga

Jun 17, 2013

Endo Pharmaceuticals Shares Climbing Higher, Up 2.0% - Financial News Network Online - Market Movers

Jun 14, 2013

Crucial Junctures May Offer Opportunity to These Companies - TheMotleyFool

Jun 13, 2013

Endo Pharmaceuticals Fulfills the Promise: Up 6.0% Since Last Week's Upgrade - Financial News Network Online - News Corner

Jun 13, 2013

Endo Pharmaceuticals Up 6.0% Since Cantor Downgraded One Week Ago (ENDP) - Financial News Network Online - News Corner

Jun 13, 2013

Infectives Partnering Terms and Agreements Report Contains Over 2,000 Links to Online Copies of Actual Infectives Deals and Contract Document - M2

Jun 12, 2013

See All News Stories on ENDP

Broker Recommendations

Current ABR	2.79
ABR (Last Week)	2.79
# of recs in ABR	19
Average Target Price	35.60
Industry Rank by ABR	110 out of 265
Rank in Industry	18 out of 95

More ENDP Broker Recommendations

Day Low - High	38.61 - 39.47
52wk Low - High	25.01 - 39.82
Previous Close	39.30
Avg. Volume	1,820,788
Industry	MED-DRUGS
Market Cap	4.41 B
Div - Yield	0.00 - 0.00
Beta	0.74
P/E (F1)	9.08
Current Year Est.	4.33
Quarterly Earnings ESP	0.00%

P/E (F1)	9.08
PEG Ratio	1.30
Current Year Est.	4.33
Current Quarter Estimate	1.16
Most Accurate Estimate	1.16
Earnings ESP	0.00%
Next Earnings Report Date	08-06-2013
EPS Last Year	5.26
Expected Earnings Growth	7.00%

Username: Password:

Remember me [?]

Endo Health Solutions Inc: (NASD: ENDP)

$38.82

-0.48 (-1.22%)

Volume 1,090,225

Jun 18 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations